Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer

PURPOSE: The purpose of this study is to retrospectively compare the efficacy and tolerability between three regimens for first-line chemotherapy—gemcitabine plus capecitabine (GEM-X), gemcitabine plus erlotinib (GEM-T), and gemcitabine monotherapy (GEM)—in patients with advanced pancreatic cancer....

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Res Treat
Hlavní autoři: Lim, Jae Yun, Cho, Jang Ho, Lee, Se Joon, Lee, Dong Ki, Yoon, Dong Sup, Cho, Jae Yong
Médium: Artigo
Jazyk:Inglês
Vydáno: Korean Cancer Association 2015
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4398119/
https://ncbi.nlm.nih.gov/pubmed/25327494
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2013.158
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky